Lyudmila K.
- Country
- Bulgaria
- Department
- #3124
Research Overview
- Phase 3 Randomized Study Comparing Asundexian and Apixaban for Stroke Prevention in Atrial Fibrillation Patients at Risk
- Evaluation of Pelacarsen (TQJ230) in Reducing Major Cardiovascular Events in Patients with Established Cardiovascular Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
- Long-term Safety and Tolerability Evaluation of Pelacarsen in Patients with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease
Data & Insights
Has run more than one trial at 225 of 640 partner sites.
Specializations
Cardiovascular Medicine
The investigator specializes in treating patients with established cardiovascular disease, with particular attention to lipoprotein management and its impact on cardiovascular outcomes.
- Major Cardiovascular Events
- Lipoprotein (a) Assessment
- Cardiovascular Risk Reduction
Their research interest extends to innovative therapeutic approaches in cardiovascular risk management.
Cardiac Electrophysiology
The investigator focuses on managing patients with atrial fibrillation, particularly those at elevated risk for stroke. Their expertise includes evaluation of anticoagulation strategies.
- Stroke Prevention
- Systemic Embolism Management
- Bleeding Risk Assessment
Their work encompasses comparative assessment of anticoagulation therapies in cardiac arrhythmia management.
Preventive Cardiology
The investigator specializes in preventive cardiology strategies, focusing on reducing cardiovascular complications in high-risk patients.
- Risk Stratification
- Preventive Interventions
- Therapeutic Innovation
Their expertise includes evaluation of novel therapeutic approaches for cardiovascular risk reduction.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.